SSG-003 for Glaucoma

SSG-003 (API: 2ccPA) is a candidate glaucoma treatment with a new mechanism of action, ATX inhibition.

•Unlike existing drugs, whose primary action is to inhibit aqueous humor production and promote outflow, this drug targets to inhibit trabecular meshwork fibrosis (sclerosis) itself and fundamentally improve the aqueous humor outflow pathway.

•Because it has a different mechanism of action from existing glaucoma treatments, a synergistic effect is expected when used in combination.

•Furthermore, in addition to its intraocular pressure-lowering effect, autotaxin's potential to protect optic nerve cells is also being studied, suggesting it may not only lower intraocular pressure but also slow the progression of glaucoma.